Drug Trial Radar · NCT03301506
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
Last checked: Nov 20, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
340
Planned (sponsor's estimate)
Start
Dec 12, 2017
Primary completion
Nov 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Oct 4, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Conditions
- Primary Biliary Cirrhosis
Interventions
Seladelpar 5 mg CapsuleDrug
Participants will be assigned to a treatment group if tolerability issues noted in the previous study.
Seladelpar 10 mg CapsuleDrug
Participants will be assigned to a treatment group unless there are tolerability issues.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment emergent adverse events (TEAEs) (National Cancer Institute {NCI} Common Terminology Criteria for Adverse Events {CTCAE} Version 5.0), biochemistry and hematology resultsTime frame: Through study completion, up to 60 Months
Locations
109 sites in 25 countries. Site status is shown where the registry gives one.
Arkansas Diagnostic Center
Little Rock, Arkansas
Stanford University School of Medicine
Palo Alto, California
California Liver Research Institute
Pasadena, California
University of California Davis Medical Center
Sacramento, California
California Pacific Medical Center
San Francisco, California
University of Colorado - Denver - PPDS
Aurora, Colorado
Yale University School of Medicine
New Haven, Connecticut
Covenant Research Fort Myers
Fort Myers, Florida
Florida Digestive Health Specialist
Lakewood Rch, Florida
University of Miami Miller School of Medicine
Miami, Florida
Covenant Research, LLC
Sarasota, Florida
Digestive Healthcare of Georgia PC
Atlanta, Georgia
University of Chicago Hospitals
Chicago, Illinois
East Jefferson General Hospital
New Orleans, Louisiana
Mercy Medical Center (Baltimore)
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center - 330 Brookline Ave
Boston, Massachusetts
Henry Ford Health System
Novi, Michigan
MNGI Digestive Health PA-Plymouth
Minneapolis, Minnesota
Southern Therapy and Advanced Research LLC
Jackson, Mississippi
Saint Louis University
St Louis, Missouri
NYU Langone Medical Center
New York, New York
Weill Cornell Medical College
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
University of Rochester Medical Center - PPDS
Rochester, New York
Duke University Medical Center
Durham, North Carolina
Northeast Clinical Research Center, LLC
Bethlehem, Pennsylvania
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Galen Medical Group
Chattanooga, Tennessee
Gastro One-8110 Walnut Run Rd
Cordova, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
Liver Institute at Methodist Dallas
Dallas, Texas
Baylor College of Medicine
Houston, Texas
The Texas Liver Institute - 607 Camden St
San Antonio, Texas
Pinnacle Clinical Research, PLLC
San Antonio, Texas
Maryview Hospital Inc., d/b/a Bon Secours Liver Institute of Hampton Roads
Newport News, Virginia
Bon Secours Richmond Community Hospital, Inc. d/b/a Bon Secours Liver Institute of Richmond
Richmond, Virginia
Liver Institute Northwest, PLLC
Seattle, Washington
Showing 40 of 109 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.